TY - JOUR
T1 - Creating novel translation inhibitors to target pro-survival proteins in chronic lymphocytic leukemia
AU - Chen, Rong
AU - Zhu, Mingzhao
AU - Chaudhari, Rajan R.
AU - Robles, Omar
AU - Chen, Yuling
AU - Skillern, Wesley
AU - Qin, Qun
AU - Wierda, William G.
AU - Zhang, Shuxing
AU - Hull, Kenneth G.
AU - Romo, Daniel
AU - Plunkett, William
N1 - Funding Information:
Acknowledgements This study was supported in part by research funding to DR and WP from a High-Impact/High-Risk Research Award from The Cancer Prevention and Research Institute of Texas, RP130660, by the CLL Global Research Foundation and the M.D. Anderson Cancer Center Moon Shots Program and cancer center support grant P30CA16622.
Publisher Copyright:
© 2019, Springer Nature Limited.
PY - 2019/7/1
Y1 - 2019/7/1
N2 - The viability of chronic lymphocytic leukemia (CLL) is critically dependent upon staving off death by apoptosis, a hallmark of CLL pathophysiology. The recognition that Mcl-1, a major component of the anti-apoptotic response, is intrinsically short-lived and must be continually resynthesized suggested a novel therapeutic approach. Pateamine A (PatA), a macrolide marine natural product, inhibits cap-dependent translation by binding to the initiation factor eIF4A. In this study, we demonstrated that a synthetic derivative of PatA, des-methyl des-amino PatA (DMDAPatA), blocked mRNA translation, reduced Mcl-1 protein and initiated apoptosis in CLL cells. This action was synergistic with the Bcl-2 antagonist ABT-199. However, avid binding to human plasma proteins limited DMDAPatA potency, precluding further development. To address this, we synthesized a new series of PatA analogs and identified three new leads with potent inhibition of translation. They exhibited less plasma protein binding and increased cytotoxic potency toward CLL cells than DMDAPatA, with greater selectivity towards CLL cells over normal lymphocytes. Computer modeling analysis correlated their structure–activity relationships and suggested that these compounds may act by stabilizing the closed conformation of eIF4A. Thus, these novel PatA analogs hold promise for application to cancers within the appropriate biological context, such as CLL.
AB - The viability of chronic lymphocytic leukemia (CLL) is critically dependent upon staving off death by apoptosis, a hallmark of CLL pathophysiology. The recognition that Mcl-1, a major component of the anti-apoptotic response, is intrinsically short-lived and must be continually resynthesized suggested a novel therapeutic approach. Pateamine A (PatA), a macrolide marine natural product, inhibits cap-dependent translation by binding to the initiation factor eIF4A. In this study, we demonstrated that a synthetic derivative of PatA, des-methyl des-amino PatA (DMDAPatA), blocked mRNA translation, reduced Mcl-1 protein and initiated apoptosis in CLL cells. This action was synergistic with the Bcl-2 antagonist ABT-199. However, avid binding to human plasma proteins limited DMDAPatA potency, precluding further development. To address this, we synthesized a new series of PatA analogs and identified three new leads with potent inhibition of translation. They exhibited less plasma protein binding and increased cytotoxic potency toward CLL cells than DMDAPatA, with greater selectivity towards CLL cells over normal lymphocytes. Computer modeling analysis correlated their structure–activity relationships and suggested that these compounds may act by stabilizing the closed conformation of eIF4A. Thus, these novel PatA analogs hold promise for application to cancers within the appropriate biological context, such as CLL.
UR - http://www.scopus.com/inward/record.url?scp=85060949419&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85060949419&partnerID=8YFLogxK
U2 - 10.1038/s41375-018-0364-x
DO - 10.1038/s41375-018-0364-x
M3 - Article
C2 - 30700841
AN - SCOPUS:85060949419
SN - 0887-6924
VL - 33
SP - 1663
EP - 1674
JO - Leukemia
JF - Leukemia
IS - 7
ER -